Integrated metabolomics and the microbiome reveal the compatibility mechanism of the Suxiao Jiuxin pill in the treatment of stable coronary artery disease.

ABSTRACT:

Background

The Suxiao Jiuxin pill (SJP) is a Chinese patent medicine that is used for the treatment of stable coronary artery disease (SCAD). However, the compatibility mechanism of SJP in treating of SCAD is still unclear. This study aimed to elucidate the serum metabolic profiles of patients with SCAD treated with SJP and to decipher the compatibility mechanism of its effective components, Chuanxiong Rhizoma and borneol.

Methods

We employed metabolomics to assess the serum metabolic profiles of SCAD patients before and after treatment with SJP through metabolomics. Additionally, the compatibility mechanism of the multicomponent pairing of Chuanxiong Rhizoma and borneol was explored using metabolomics and 16S rRNA sequencing.

Results

Our findings indicate that SJP si

SUBMITTER: Le W 

PROVIDER: S-EPMC12400554 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature